Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.

Kazuhisa SugiuHiroshi Tazawa Joe Hasei Yasuaki YamakawaToshinori OmoriTadashi KomatsubaraYusuke Mochizuki Hiroya Kondo Shuhei Osaki Tomohiro Fujiwara Aki Yoshida Toshiyuki Kunisada Koji UedaYasuo UrataShunsuke KagawaToshifumi OzakiToshiyoshi Fujiwara

Published in: Cancer chemotherapy and pharmacology (2021)

Our results suggest that MDR1 is an attractive therapeutic target for chemoresistant OS. Tumor-specific virotherapy is thus a promising strategy for reversing chemoresistance in OS patients via suppression of MDR1 expression.

Keyphrases

multidrug resistant
poor prognosis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes